The putative antidepressant DOV 216,303, a triple reuptake inhibitor, increases monoamine release in the prefrontal cortex of olfactory bulbectomized rats.

@article{Prins2010ThePA,
  title={The putative antidepressant DOV 216,303, a triple reuptake inhibitor, increases monoamine release in the prefrontal cortex of olfactory bulbectomized rats.},
  author={Jolanda Prins and Damiaan Denys and Koen G C Westphal and Gerdien A. H. Korte-Bouws and Maria S. Quinton and Rudy Schreiber and Lucianne Groenink and Berend Olivier and S Mechiel Korte},
  journal={European journal of pharmacology},
  year={2010},
  volume={633 1-3},
  pages={55-61}
}
The first line of antidepressant treatment nowadays are selective serotonin reuptake inhibitors. Although they are relatively safe to use, selective serotonin reuptake inhibitors (SSRIs) can induce severe side effects. New promising antidepressants may be the triple monoamine reuptake inhibitors, which not only enhance serotonin and norepinephrine neurotransmission, but also increase brain dopamine levels. Recently it has been shown that one of the triple reuptake inhibitors, DOV 216,303 has… CONTINUE READING